The use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) as one of the pharmacological alternatives for patients with Alzheimer's Disease: a systematic literature review

Authors

DOI:

https://doi.org/10.33448/rsd-v10i16.23609

Keywords:

Alzheimer's Disease; Neurodegenerative; Pharmacotherapy; INEs.

Abstract

Introduction: Inflammatory response in AD is characterized by the presence of activated microglia (the resident immunocompetent cells of the brain) in close association with neuritic plaques. Current evidence suggests that microglia are primarily involved in phagocytic activity and may be responsible for inducing additional neuronal damage by generating oxygen species and proteolytic enzymes. If anti-inflammatory drugs protect against the neurodegeneration seen in the brain of AD patients, then patients with a history of anti-inflammatory use should have a reduction in pathological changes in the brain and brain inflammation. Objective: to explain about the use of non-steroidal anti-inflammatory drugs as drug therapy for Alzheimer's disease. Results: Brain inflammation is believed to contribute to the pathological features of Alzheimer's disease (AD), and it has been postulated that anti-inflammatories protect against this tissue damage. However, one of the controversial factors regarding the use of non-steroidal anti-inflammatory drugs to reduce the risk of developing Alzheimer's disease is the toxicity associated with these drugs. Methodology: This is a systematic literature review with works searched in the following databases: National Library of Medicine (PubMed MEDLINE), Scientific Electronic Library Online (Scielo), Cochrane Database of Systematic Reviews (CDSR), Google Scholar, Library Health Virtual (BVS) and EBSCO Information Services. Relevant sources inherent to the theme were analyzed, using as one of the main criteria the choice of current, original and international articles. A total of 12 scientific articles were available for review. Final considerations: Anti-inflammatory drugs have been suggested as a possible treatment for Alzheimer's disease (AD). The association of immune proteins and immunocompetent microglial cells with senile plaques (SP) in AD and normal aging suggests that these drugs may be able to modify the course of AD, either interfering with SP formation or suppressing inflammation.

References

Aisen, P. S., et al. (2003). Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA, 289 (8), 2819-2826.

Brown, G. C., et al. (2003). Inflammatory neurodegeneration mediated by nitric oxide, glutamate and mitochondria. Mol Neurobiol., 27(3), 325-355.

Forlenza, O. V. (2005). Tratamento farmacológico da doença de Alzheimer. Rev Psiq Clin., 32 (3), 137-148.

Gyengesi, E., et al. (2020). In search of an anti-inflamatory drug for Alzheimer disease. News & Views, 16 (8), 131-133.

Hoozemans, J. J., et al. (2003). Non-steroidal anti-inflammatory drugs and cyclooxygenase in Alzheimer's disease. Curr Drug Targets., 4(6), 461-468.

Mackenzie, I. R. (2001). Postmortem studies of the effect of anti-inflammatory drugs on Alzheimertype pathology and associated inflammation. Neurobiol Aging, 22(6), 819-822.

McGeer, P. L., et al. (2006). Inflamação, agentes anti-inflamatórios e doença de Alzheimer: últimos 12 anos. IOS Press Content Library, 6 (8), 271-276.

Moore, A. H., et al. (2002). K. Neuroinflammation and anti-inflammatory therapy for Alzheimer's disease. Adv Drug Deliv Rev., 54(12), 1627-1656.

Parihar, M. S., et al. (2004). Alzheimer's disease pathogenesis and therapeutic interventions. J Clin Neurosci., 11(5), 456-467.

Reines, S. A., et al. (2004). Rofecoxib: no effect on Alzheimer´s disease in a 1-year, randomized, blinded, controlled study. Neurology, 62 (1), 66-671

Scali, C., et al. (2003). The selective cyclooxygenase-2 inhibitor rofecoxib suppresses brain inflammatory and protects cholinergic neurons from excitotoxic degeneration in vivo. Neuroscience, 117(4), 909-919.

Sereniki, A., et al. (2008). A doença de Alzheimer: aspectos fisiopatológicos e farmacológicos. Rev Psiq RS, 30 (1), 1-17.

Tuppo, E. E., et al. (2005). The role of inflammation in Alzheimer's disease. Int J Biochem Cell Biol., 37(2), 289-305.

Published

09/12/2021

How to Cite

OLIVEIRA, N. S. S.; MORAIS, A. F. B. de .; TAVARES, A. P. G.; FIGUEIREDO, B. Q. de .; MATOS, B. A. de .; AMORIM, G. S.; MIRANDA, L. D.; OLIVEIRA, R. C. The use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) as one of the pharmacological alternatives for patients with Alzheimer’s Disease: a systematic literature review. Research, Society and Development, [S. l.], v. 10, n. 16, p. e146101623609, 2021. DOI: 10.33448/rsd-v10i16.23609. Disponível em: https://www.rsdjournal.org/index.php/rsd/article/view/23609. Acesso em: 19 apr. 2024.

Issue

Section

Health Sciences